COMMUNIQUÉS West-GlobeNewswire

Enlivex Therapeutics To Present At The 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.
04/09/2019
Nes-Ziona, Israel, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation at the [...]
vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
04/09/2019
HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and [...]
Teewinot Life Sciences Expands First in Class Intellectual Property Portfolio for the Production of Cannabinoids and Novel Derivatives
04/09/2019
Receives five new patents across strategic areas including biocatalytic manufacturing processes, generation of new chemical entities (NCEs) and cannabinoid formulations Proprietary CannSynthesis® technology platform is [...]
Orchestra BioMed Receives CE Mark for BackBeat Cardiac Neuromodulation Therapy™ (CNT) for Hypertension
04/09/2019
Late-breaking BackBeat CNT™ randomized, double-blind clinical results selected by Cardiovascular Research Foundation for presentation at TCT 2019 NEW HOPE, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Orchestra BioMed™, Inc [...]
Auxly, Together with its Strategic Partner, Atlantic Cultivation, Enters into a Comprehensive Supply, Development and Retail Agreement with Newfoundland & Labrador
04/09/2019
VANCOUVER, British Columbia, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (" Auxly " or the " Company "), together with its strategic partner, Atlantic Cultivation ( “Atlantic” ), is [...]
Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors
04/09/2019
EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]
Orchard Therapeutics Announces Encouraging Update from Proof-of-Concept Study of OTL-203 for the Treatment of Mucopolysaccharidosis Type I (MPS-I)
04/09/2019
Six of Eight Patients Treated to Date with Follow-up Out to 12 Months in First Patient to Receive Treatment Evidence of Engraftment and Peripheral Blood Alpha-L-iduronidase (IDUA) Enzyme Overexpression Across Cohort [...]
Auris Medical Announces Appointment of New Chief Financial Officer
04/09/2019
Hamilton, Bermuda, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology [...]
Oxford Biomedica Interim Results
04/09/2019
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2019 Oxford, UK – 4 September 2019: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today [...]
Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
04/09/2019
BERKELEY HEIGHTS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019
04/09/2019
CRANBURY, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell, President and Chief [...]
Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie
04/09/2019
EXTON, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research- [...]
Prevail Therapeutics to Present at Morgan Stanley 2019 Global Healthcare Conference
04/09/2019
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients [...]
Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder
04/09/2019
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that participants were dosed in a Phase [...]
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/09/2019
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired [...]
Oncology Venture appoints new CEO and CFO and proposes rights issue to facilitate a focused commercial strategy
04/09/2019
Press release Hoersholm, Denmark, September 4, 2019 – Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) today announces the appointments of a new CEO and a new CFO, and its plan to propose a [...]
XORTX Highlights New Research on Polycystic Kidney Disease Awareness Day
04/09/2019
● New Study Shows a Novel Form of Injury Linking Uric Acid Crystals in Urine and ADPKD Progression ● CALGARY, Alberta, Sept. 04, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX [...]
Oxurion Completes Enrolment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME)
04/09/2019
Company on Track for Data Read Out by End of 2019 Leuven, Belgium, 4 September 2019 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision [...]
Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS
04/09/2019
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neurofilament light chain [...]

Pages